AJP - Renal Watch the video to learn how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Renal Physiol 295: F1213-F1221, 2008. First published July 23, 2008; doi:10.1152/ajprenal.90216.2008
0363-6127/08 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
295/4/F1213    most recent
90216.2008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Veuthey, T.
Right arrow Articles by Roque, M. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Veuthey, T.
Right arrow Articles by Roque, M. E.

Role of the kidney in iron homeostasis: renal expression of Prohepcidin, Ferroportin, and DMT1 in anemic mice

Tania Veuthey, María Cecilia D'Anna, and Marta Elena Roque

Laboratory of Human Physiology, Departament of Biology, Biochemistry and Pharmacy, Universidad Nacional del Sur, Bahia Blanca, Argentina

Submitted 27 March 2008 ; accepted in final form 18 July 2008


    ABSTRACT
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
It is known that renal tissue plays a role in normal iron homeostasis. The current study examines kidney function in iron metabolism under hemolytic anemia studying renal expression of Prohepcidin, Ferroportin (MTP1), and divalent metal transporter 1 (DMT1). The relationship between these proteins and iron pigments was also investigated. Immunohistochemical procedures to study renal expression of Prohepcidin, MTP1, and DMT1 were performed in healthy and anemic mice. Renal tissue iron was determined by Prussian blue iron staining. To assess anemia evolution and erythropoietic recovery, we used conventional tests. In healthy mice, Prohepcidin expression was marked in proximal tubules and inner medulla and absent in outer medulla. Cortical tissue of healthy mice also showed MTP1 immunostaining, mainly in the S2 segment of proximal tubules. Medullar tissue showed MTP1 expression in the inner zone. In addition, S2 segments showed intense DMT1 immunoreactivity with homogeneous DMT1 distribution throughout renal medulla. The main cortical findings in hemolytic anemia were in S2 segments of proximal tubules where we found that decreased Prohepcidin expression coincided with an increment in Ferroportin and DMT1 expression. This expression pattern was concomitant with increased iron in the same tubular zone. However, in medullar tissue both Prohepcidin and MTP1 decreased and DMT1 was detected mainly in larger diameter tubules. Our findings clearly demonstrate that in hemolytic anemia, renal Prohepcidin acts in coordination with renal Ferroportin and DMT1, indicating the key involvement of kidney in iron homeostasis when iron demand is high. Further research is required to learn more about these regulatory mechanisms.

divalent metal transporter 1; anemia


HEPATIC HEPCIDIN IS A KEY protein in iron metabolism (23, 29), acting as a physiological regulator of this metal (24, 29). Hepcidin has been implicated as the "stores regulator," a putative factor that signals the iron content of the body to intestinal cells (12). Its synthesis is reduced in conditions of increased iron demand, such as anemia (24).

Furthermore, it is known that control of iron in the body is mainly dependent on tight regulation of gastrointestinal (GI) uptake from the diet to balance iron loss by other ways (12). Renal excretion is central to the control of other divalent cations, but little is actually known about how the kidney handles iron. A few years ago Wareing et al. (34) reported not only that a significant amount of serum iron is available for glomerular ultrafiltration, but also that most of the filtered iron is reabsorbed in renal tubules. However, it is unclear whether this organ exerts any control over the amount of iron excreted (34).

The recent finding that hepcidin is present in renal cells in basal conditions provides us with a new window on the hepcidin-dependent role of the kidney in iron homeostasis (16).

In this context, identification and characterization of transmembrane iron proteins like Ferroportin and divalent metal transporter 1 (DMT1) have greatly advanced our knowledge of iron transport. Ferroportin, also known as Ireg1 or MTP1, is an iron export protein that acts as an iron efflux transporter in several tissues (8, 21). It was originally isolated from duodenal mucosa in basal conditions, where expression was high in basal membrane to facilitate iron transport from the enterocyte to the bloodstream (21), suggesting its involvement in maintaining body iron stores. Other sites of high expression are macrophages, particularly those in the red pulp of the spleen and Kupffer cells of the liver (18). There is evidence that MTP1 is also expressed in renal cells located on the glomerulus and proximal tubular cells of this tissue (1, 20). These latter results contribute to the hypothesis of its renal involvement in iron homeostasis regulation.

Nemeth et al. (22) reported a hepcidin-Ferroportin interaction which could be central in iron physiopathology, supporting the hypothesis that Ferroportin is the receptor for hepcidin.

Another key protein involved in iron metabolism is DMT1, identified in rat duodenum as being capable of transporting iron and other metal ions (13). DMT1 transport is pH dependent, optimal at acid pH (5.5 to 6.0), electrogenic, and associated with a proton cotransport (13). Alternative splicing of the DMT1 gene produces two isoforms distinguished by the presence (isoform I) or absence (isoform II) of an iron response element (IRE) in the 3' untranslated region, both being competent in iron transport. DMT1 has been studied in duodenum where modulation of dietary iron absorption is the main mechanism for regulating body iron balance. Expression of DMT1 is reduced in iron-enriched diets but increases when iron intake is restricted (5). The converse is true in liver, since this organ acts as a reservoir of iron. High levels of dietary iron produce an increase in DMT1 expression in hepatocytes, promoting iron acquisition, whereas low levels decrease hepatic DMT1 expression, causing a reduction in iron accumulation (26, 32). Although kidney is not usually associated with serum iron balance, several studies found renal DMT1 expression in mice and rats, suggesting that this organ may have a role in iron homeostasis (4, 10, 33). Furthermore, Wareing et al. (34) reported a decrease in urinary iron levels, suggesting iron reabsorption in renal tubules.

Chronic kidney disease patients gradually develop anemia, and despite maintenance erythropoietin therapy they frequently present functional iron deficiency. In cases such as these, persistently high levels of hepatic hepcidin expression, probably due to chronic inflammatory state, may explain why duodenal iron absorption remains inadequately low and the iron sequestration within cells of the reticuloendothelial system is high (19). In view of the relationship between hepcidin and the iron transporters Ferroportin and DMT1, an experimental model studying these proteins will serve to elucidate modifications in renal pathways in anemia associated with chronic kidney diseases.

Since renal involvement in iron homeostasis regulation remains poorly understood, the purpose of the present study was to determine renal expression of Prohepcidin in hemolytic anemia, and its relationship with the iron transporters DMT1 and Ferroportin.


    MATERIALS AND METHODS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Animals. Adult female mice (CF1) were bred at the animal facility of the Universidad Nacional del Sur. The animals were kept in cages at controlled room temperature and humidity during 10 days before the commencement of the study and were fed throughout on a standard diet with access to water ad libitum, under standard conditions: a 12:12-h, light-dark period. The initial body weight of each mouse in the group was similar (35 ± 2.3 g) and weight was controlled throughout the study. The procedures followed are in line with the Guide for the Care and Use of Laboratory Animals. Before the initiation of this study, the protocol was approved by the Assessor Committee of Animal Use of the Universidad Nacional del Sur.

Experimental design. After acclimatization, the animals were divided into two groups (16 mice per group): 1) nonanemic mice receiving saline solution intraperitoneally (0.9% NaCl) on days 0 and 2; and 2) anemic mice receiving phenylhydrazine (PHZ) dissolved in 0.5 ml of saline solution intraperitoneally on days 0 and 2. The PHZ concentration injected was 60 mg/kg body wt.

Mice of both groups were subject to blood controls on day 0, before PHZ or saline solution administration. Anemia evolution and erythropoietic recovery were assessed using conventional hematological tests on days 3, 4, and 5. Animals were anesthetized with ketamine (50 mg/kg)-xylazine (20 mg/kg) for blood collection. For each time point, samples from three individual mice from each group were collected from the retro-orbital venous plexus (25 µl each).

PHZ preparation. PHZ (Sigma Chemical) in 0.1 M potassium phosphate buffer pH 7.4 was prepared on day 0. The solution was sterilized by filtration before use and administered by intraperitoneal injection on days 0 and 2.

Hematology. The following tests were performed on EDTA samples: hemoglobin (Hb), hematocrit (HCT), reticulocytes, and Heinz body counts. Reticulocytes were counted in blood smears stained with Brilliant Cresyl Blue. Each reticulocyte count was based on a count of 1,000 red blood cells (RBC). Differential Heinz body RBC count was obtained by counting 1,000 cells in a Brilliant Cresyl Blue-stained preparation. Blood smears were prepared immediately after blood sample collection and were stained with May Grünwald-Giemsa. Cell count was performed three times for each time point and for each group.

Tissue harvestation at necropsy. On days 0, 3, 4, and 5, a subset of each group (n = 3) was anesthetized with an intraperitoneal injection of pentobarbital sodium (50 mg/kg body wt) to perfuse kidneys. Immediately after the animals were killed by cervical dislocation, renal tissue of both control and PHZ-treated mice (60 mg/kg) was removed under sterile conditions by abdominal incision and separated from the surrounding organs. The tissues were kept in sterile saline solution. Histological techniques were followed using Ringer solution plus heparin (0.25% wt/vol) and Bouin solution as perfusion liquids. Approximately 25 ml of solution were perfused in each organ to wash out the red cells.

Antibodies. DMT1 immunodetection was performed using an affinity-purified rabbit anti-mouse polyclonal antibody directed against the peptide VKPSQSQVLRGMFV, which corresponds to amino acids 229-242, common to isoforms I and II (kindly provided by S. Gauthier, Canada). For Ferroportin detection, an affinity-purified rabbit anti-mouse polyclonal antibody directed against COOH-terminal segments (kindly provided by B. Galy, Germany) was used. Prohepcidin immunodetection was performed with an anti-mouse Pro-Hepcidin (Alpha Diagnostic). Goat-labeled polymer-horseradish peroxidase anti-rabbit Envision+System (DAB; Dako Cytomation) was used as secondary antibody.

Immunohistochemistry technique. Kidney samples from control and PHZ-treated mice (60 mg/kg) were postfixed by immersion in fresh fixative solution (10% neutrally buffered formalin, pH 7.2) and embedded in paraffin. Sections of 5 µm were obtained and mounted on glass slides. Before labeling, sections were deparaffinized in xylene and rehydrated in a graded series of ethanol baths. Endogenous peroxidase activity in deparaffinized sections was blocked with 3% H2O2. Sections were then incubated in PBS for 30 min at room temperature. Incubation with the primary antibody diluted into PBS (pH 7.1) was carried out in a wet chamber for 1 h at room temperature for DMT1 and MTP1, and overnight at 4°C for Pro-Hepcidin immunodetection. Dilutions of antibodies were as follows: anti-DMT1 (1:1,000), anti-MTP1 (1:500), and anti-Prohepcidin (1:100). Following incubation with the primary antibody, the tissues were washed with PBS, incubated with a goat anti-rabbit IgG peroxidase-coupled secondary antibody for 30 min at room temperature, and then rewashed with PBS. Subsequent localization of proteins was revealed by reaction with 3'-diaminobenzidine tetrahydrochloride (DAB) in solution. Sections were then counterstained with Harris hematoxilin. Finally, sections were dehydrated in ethanol and xylene and mounted on coverslips. Negative controls included incubation with PBS without the primary antibody. Immunostaining was analyzed with an Olympus BX51 microscope using x10 and x40 dry objectives and a x100 oil immersion objective. Digital images were obtained with an Olympus C7070 camera.

Tissular iron. To determine iron store, Prussian blue iron staining was performed in sections of mouse kidney, following the manufacturer's instructions. The technique is based on the ability to release ferric iron from protein-bound tissue deposits, which in the presence of ferrocyanide ions is precipitated as the highly colored and highly water-insoluble complex, potassium ferric ferrocyanide, Prussian blue.

To carry out the stain, sections were deparaffinized and hydrated to distilled water. Slides were incubated with 10% potassium ferrocyanide for 4 min followed by incubation with potassium ferrocyanide-hydrochloric acid for 12 min. Sections were then rinsed well in distilled water, counterstained with nuclear fast red for 1 and 30 min, and finally rinsed in distilled water, dehydrated, cleared, and mounted.

Proximal tubule identification. Proximal and distal tubules are two of several structures contained in the renal cortex. The following criteria were used to identify proximal tubules (4): 1) their predominance in outer medullary rays, 2) the fact that they are most abundant in the cortex, and 3) their epithelium is taller and the lumen much narrower. Different segments of proximal tubules were distinguished as follows: 1) S1 and S2 segments are in the cortical zone close to the glomeruli, whereas S3 segments lie in outer strip of the outer medulla and 2) S1 and S3 segments have taller epithelium and narrower lumen than S2 segments.

Statistical analysis. At least four individuals were tested in each mouse experiment. Data were analyzed by one-way ANOVA followed by the Tukey multiple comparison test. The level of statistical significance was set at P < 0.05. All values are expressed as means ± SD.


    RESULTS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Hematological studies. Hematological data in healthy (day 0, HCT: 48.0 ± 0.5%; Hb: 15.4 ± 0.75 g/dl) and anemic mice (days 3 and 4, HCT: 33.5 ± 1.5%; Hb: 10.0 ± 0.8 g/dl) showed the development of an anemic state in the latter. The reticulocyte count showed normal values in healthy mice (4.3 ± 0.2%) and an increment associated with an intense oxidative damage in anemic mice (day 3: 42 ± 3.16; and day 4: 51.6 ± 2.12%). On day 5, a reverse trend toward control values was observed (HCT: 38.0 ± 1.8%; Hb: 11.3 ± 0.6 g/dl; reticulocyte: 30.3 ± 3.5%).

Prohepcidin. The immunohistochemical study of medullar tissue in the basal condition (nonanemic mice) showed Prohepcidin expression with intracytoplasmic localization in the inner medulla (Fig. 1A). Under severe hemolysis, a decrease in staining was seen in the inner medulla compared with the basal condition (Fig. 1B). The outer medullar zone was negative for Prohepcidin expression both in the basal and anemia conditions (data not shown).


Figure 1
View larger version (185K):
[in this window]
[in a new window]

 
Fig. 1. Prohepcidin immunohistochemistry in renal tissue of healthy and anemic mice. A: inner medulla tubules of healthy mice showing intense Prohepcidin immunostaining with intracellular localization (arrow; x400). B: inner medulla tubules of anemic mice showing low Prohepcidin immunostaining (arrow; x400). C: cortex of healthy mice showing Prohepcidin expression in proximal tubules. The intensity of immunostaining was strong in S2 (arrow), weak in S1, and negative in S3 segments. Other cortical structures were negative for Prohepcidin (x200). D: cortex of anemic mice showing weak Prohepcidin expression in proximal tubules. The intensity of immunostaining was strong in S2 (arrow) and weak in S1. No staining was detected in S3 segments (arrowheads) or in other cortical structures (x200). E: cortex of healthy mice showing intracellular Prohepcidin localization in S2 segments of proximal tubules, near to cell basal membrane (arrow; x1,000). F: medulla negative control (x400). Tissue was incubated with PBS without the primary antibody. G: cortical negative control (x400). Tissue was incubated with PBS without the primary antibody. Kidney tissue sections prepared as described under MATERIALS AND METHODS were stained with polyclonal rabbit a-Prohepcidin antiserum (A, B, D, E, F). Negative controls (F, G). Scale bars: 20 µm.

 
In the renal cortical zone, we observed Prohepcidin expression in proximal tubules in basal conditions (nonanemic mice). However, its expression in glomeruli, parietal Bowman's epithelium, and blood vessels was negative (Fig. 1C). When we undertook a more detailed analysis of cortical tissue, we observed strong hepcidin immunoreactivity in S2 segments of proximal tubule, decreasing toward S1 segments (Fig. 1C). Prohepcidin localization in proximal tubules was intracellular and close to the basal membrane (Fig. 1E). Conversely, we did not detect the protein in S3 segments. Cortical examination throughout severe hemolysis revealed Prohepcidin expression in proximal tubules, with intense immunostaining in S2 segments, weaker staining in S1 segments, and no staining in S3 segments (Fig. 1D). Along these tubules Prohepcidin localization was intracytoplasmic, close to the basal membrane. The only difference between anemic and nonanemic mice was that the intensity of immunostaining was lower in the former group. As in the case of basal conditions, immunostaining was not observed in other cortical structures.

Ferroportin. The study of MTP1 distribution in renal medullar tissue in basal conditions revealed weak immunoreactivity in tubules of the inner medulla (Fig. 2A). Specific immunostaining was observed mainly in the intracellular zone in these tubules and none in the basal membrane (Fig. 2B). Outer medulla only showed MTP1 expression in bundles of vessels and in some tubules, being weak and intracytoplasmic (data not shown).


Figure 2
View larger version (110K):
[in this window]
[in a new window]

 
Fig. 2. MTP1 immunohistochemistry in renal tissue of healthy and anemic mice. A: inner medulla of healthy mice showing intense MTP1 expression, mainly intracellular (arrow), and absent in basal membrane (x400). B: inner medulla of healthy mice showing intracellular immunostaining in these tubular structures (arrow; x1,000). C: inner medulla of anemic mice showing weak MTP1 expression in these tubular structures, compared with tissue of healthy mice (arrow; x400). D: inner medulla of anemic mice showing weak intracellular MTP1 expression (arrow; x1,000). E: proximal tubules of healthy mice showing MTP1 immunostaining mainly in S2 segment with intracytoplasmic localization (arrow) and on the apical membrane (arrowhead). Other cortical structures were negative for Ferroportin (x400). F: proximal tubules of healthy mice showing MTP1 immunostaining in S2 segment, with intracytoplasmic localization close to the basal membrane (arrow) and on the apical membrane (arrowhead; x1,000). G: proximal tubules of anemic mice showing intense MTP1 immunoreactivity in S2 with intracytoplasmic localization (arrow) and on the apical membrane (arrowhead; x400). H: proximal tubules of anemic mice showing intracellular MTP1 localization, near to basal membrane (arrow) and on apical membrane (arrowhead). As with healthy mice, other cortical structures remained negative for Ferroportin (x1,000). I: medulla negative control (x400). Tissue was incubated with PBS without the primary antibody. J: cortical negative control (x400). Tissue was incubated with PBS without the primary antibody. Kidney tissue sections prepared as described under MATERIALS AND METHODS were stained with polyclonal rabbit a-MTP1 antibody (A, B, C, D, E, F, G, H). Negative controls (I, J). Scale bars: 20 µm.

 
When we studied this iron transporter in medullar tissue along hemolytic anemia, the main difference was observed on day 4, when the inner medulla showed a weaker immunostaining than that observed at the commencement of the study (Fig. 2, C and D). The study of renal medulla on day 5 (anemia restoration) showed the same pattern of MTP1 expression as observed in basal conditions (data not shown).

In nonanemic mice, we detected MTP1 expression in structures like proximal tubules (Fig. 2E), with intracytoplasmic localization near to the basal membrane as well as in apical cytoplasm (Fig. 2F). Other tubular structures not clearly identifiable also showed positive. In a more detailed study, we observed intense immunostaining in S2 segments, weaker staining in S1 segments, and a total absence of staining in S3 segments (Fig. 2E). Other cortical structures were negative for this iron transporter.

Along the anemic state, we observed the main differences in MTP1 expression on days 4 and 5. The cortical study showed an increase in MTP1 immunostaining in the same renal tubular structures as those seen in control tissue. S2 and S1 segments showed more intense staining, whereas S3 segments were negative for Ferroportin expression (Fig. 2G). In addition, subcellular localization of this protein remained mainly intracellular near to the basal membrane, although MTP1 staining can be observed over the brush border (Fig. 2H). Other cortical structures remained negative.

DMT1. In nonanemic mice, we detected intracellular DMT1 expression with homogeneous distribution through renal medulla (Fig. 3A) with intracellular localization (Fig. 3B). The pattern of DMT1 expression was studied along the instauration of the anemic state and after the restitution of erythropoietic activity. On day 3, we detected DMT1 mainly in large diameter tubules of the inner medulla with intracellular localization (Fig. 3, C and D). As in the case of basal conditions, no changes were observed in outer medulla staining (data not shown).


Figure 3
View larger version (98K):
[in this window]
[in a new window]

 
Fig. 3. DMT1 immunohistochemistry and tissular iron in renal tissue of healthy and anemic mice. A: inner medulla of healthy mice showing homogeneous DMT1 distribution along the tissue (x400). B: inner medulla of healthy mice showing DMT1 expression with intracellular localization (arrow; x1,000). C: inner medulla of anemic mice showing intense DMT1 expression in major diameter tubules (arrow; x400). D: inner medulla of anemic mice showing DMT1 expression with intracellular localization (arrow; x1,000). E: proximal tubules of healthy mice showing intense DMT1 immunoreactivity. The immunostaining was intense in S2 (arrow). Other cortical structures were negative for DMT1 (x400). F: proximal tubules of healthy mice showing DMT1 expression in S2 segments with intracellular localization close to the apical membrane (arrow; x1,000). G: proximal tubules of anemic mice showing intense DMT1 staining in S2 segments (arrow). As with healthy mice, other cortical structures remained negative for DMT1 (x400). H: proximal tubules of anemic mice showing DMT1 localization in S2 segments, with intracellular localization and close to the apical membrane (arrow; x1,000). I: cortical structures of healthy mice showing absence of tissular iron deposits in tubular structures (x400). J: cortical structures of anemic mice showing tissular iron. Deposits were intense in S1 and S2 segments of proximal tubules (arrow) and negative in S3 segments. As with healthy mice, other cortical structures show no tissular iron (x400). Kidney tissue sections prepared as described under MATERIALS AND METHODS were stained with polyclonal rabbit a-DMT1 antibody (A, B, C, D, E, F, G, H). Tissular iron was detected as described in MATERIALS AND METHODS (I, J). Scale bars: 20 µm.

 
DMT1 expression in renal tissue sections from day 4 showed minor differences between the inner and outer medulla compared with day 3 sections. In renal inner medulla, differences remained, although were less evident, between the staining in tubules of large diameter and those of small diameter. Outer medulla showed the same immunostaining pattern as basal tissue (data not shown).

The renal cortical zone of nonanemic mice revealed an abundance of this iron transporter in structures like proximal tubules, where DMT1 localization was intracellular, near to the apical membrane (Fig. 3F). Upon more detailed study to identify which specific segments of proximal tubules were stained, we detected more intense immunoreactivity in S2 and S3 segments and weaker immunoreactivity in S1 segments. We did not detect any DMT1 immunostaining in the parietal Bowman's epithelium, blood vessels, and glomeruli (Fig. 3E).

The same pattern of DMT1 distribution was observed on day 3 as in control tissue, with specific immunoreactivity in proximal tubules being localized in cytoplasm near to apical membrane (Fig. 3H). The staining detected in S3 had the same intensity as in the control. S2 segments on the other hand showed an increment in DMT1 expression with respect to the basal state, with S1 segments maintaining a weak DMT1 expression (Fig. 3G). No changes were observed in the renal cortical zone of anemic mice on day 4 with respect to basal conditions. On day 5, as in the basal state, we observed DMT1 expression in the renal cortical zone and in medulla.

Tissular iron. Renal tissue of anemic mice showed abundant iron deposits in the cortical zone (Fig. 3J), whereas there were no iron deposits in the basal condition (Fig. 3I). Medullar structure showed an absence of tissular iron in anemic and nonanemic mice (data not shown).

The histological examination on day 3 of hemolytic anemia revealed the presence of iron in structures whose morphology was similar to that of proximal tubules. A more detailed assessment showed strong iron deposits in S1 and S2 segments but none in S3 segments (Fig. 2J). There was a clear intracellular localization of iron in these structures. The monitoring of iron deposits on days 4 and 5 in this experimental design showed morphological changes similar to those occurring on day 3.


    DISCUSSION
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
The current paper reports the renal expression of Prohepcidin and the iron transporters DMT1 and MTP1 in healthy and anemic mice. This is the first study to show changes in these proteins in renal tissue under severe hemolysis.

Renal Prohepcidin expression. In hemolytic anemia, Prohepcidin immunostaining decreased significantly in renal inner medulla with respect to basal conditions. This finding is crucial to understand renal involvement in iron metabolism.

The distribution pattern in the inner medulla of healthy mice was found to coincide with that observed by Kulakzis et al. (16), although under our assay conditions we were unable to identify the protein in the outer medulla.

Our findings in hemolytic anemia demonstrate a clear decrease in the intensity of cortical Prohepcidin expression. Although Kulakzis et al. (16) found no evidence of proximal Prohepcidin expression in healthy mice, in our study we observed intense immunostaining in S2 segments of proximal tubules.

It is important to note that Prohepcidin localization was strictly associated with basal membrane, possibly suggesting a close interaction with MTP1, the molecule proposed as the hepcidin receptor (22).

Our findings suggest that the high Epo levels present in hemolytic anemia may be responsible for the reported negative regulation of hepatic hepcidin (24) and for the low renal expression of this peptide found by us. Several hypotheses could explain our findings. First, it is known that the kidney is closely associated with erythropoiesis since low levels of oxygen present in hemolytic anemia induce increases in HIF-1, which in turn plays an important role in the expansion of committed erythroid progenitors and in the terminal differentiation of erythroid cells (31). This could explain hematological restoration to hemolytic anemia (6, 14).

Although hemolytic anemia causes hypoxemia, it is not clear whether hepcidin regulation by oxygen is independent of the pathway via anemia. Nor is it clear as yet whether hypoxia or other systemic signals are involved in the synthesis and expression of Prohepcidin. Second, although there is abundant blood flow to the kidney (9), it is known that cortical tissue is very sensitive to hypoxic conditions and that peritubular fibroblasts in this zone produce erythropoietin under hypoxia (17). Moreover, some studies reported that hepatic synthesis of hepcidin is suppressed in anemia induced by hemolysis (24) and that a potent downregulation of hepcidin expression in the liver is observed after erythropoietin administration (25). Finally, Dallalio et al. (7) showed that there is a significant decrease in colony formation in the presence of hepcidin, suggesting an additional mechanism by which hepcidin can inhibit erythropoiesis.

Although the relationship between Epo and hepcidin has been demonstrated, the specific mechanisms that regulate Prohepcidin renal expression in hemolytic anemia, a state with high Epo levels, are not known. It is possible that direct and/or indirect pathways are involved.

Renal Ferroportin expression. Another objective was to study the relationship between Prohepcidin and renal MTP1 expression in hemolytic anemia. A recent study reports MTP1 expression and the mRNA of this protein in renal tissue of healthy mice (22). However, little information is available in the literature on the subcellular localization of this exporter in healthy mouse kidney, and even less on immunohistochemical changes in hemolytic anemia. The main contribution of the present study is therefore the reported evidence of the presence of MTP1 in renal tissue under severe anemia.

The increased MTP1 immunostaining seen on S1 and S2 segments of proximal tubules under hemolytic stimuli suggests its involvement in the movement of iron into the bloodstream to increase iron availability and prevent loss of iron through urine.

The strong intracellular expression observed in the basal cytoplasm suggests that as reported by Oates and Thomas (27) in intestinal cells, MTP1 can transport iron into organelles to internalize iron in the cell. This could allow the subsequent export of iron to the plasma, since it is known that high iron demand is common in anemia. However, the reason for this behavior in renal tissue requires further study.

It is important to note that in healthy mice Ferroportin was seen both in basal as well as in apical cytoplasm of proximal tubules. The basal localization of Ferroportin is consistent with its role as iron exporter, which is enhanced in anemic state. The finding about apical localization in healthy state is in accordance with the reports by Oates and Thomas (28) on duodenum and it could be indicating a modulation of DMT1 activity by Ferroportin on apical surface.

We observed a decrease in MTP1 staining in the inner medulla of anemic mice compared with healthy mice. This could be the consequence of coordinated activity in the different renal zones, some structures having weak activity and others playing a major role in the process of iron reabsorption in renal tissue. Possibly, these changes allow iron reabsorption in anemia in certain areas of the kidney closely associated with iron homeostasis. However, the mechanisms responsible for variations in Ferroportin expression in different zones of the kidney are not known.

Interestingly, we found an inverse relationship between hepcidin and Ferroportin in basal conditions. High Prohepcidin expression was observed in conjunction with weak MTP1 expression throughout a downregulation mechanism.

In support of these findings, a recent study indicated that Ferroportin is regulated by hepcidin through the direct binding of hepcidin to Ferroportin on cell membranes, causing its internalization and degradation inside the cell (22).

Renal DMT1 expression. Renal DMT1 is another iron protein that to date has not been studied in depth in hemolytic anemia. Our results showing intense DMT1 expression in medulla in anemia are in agreement with those reported in animals on an iron-restricted diet, a condition of increased iron demand (33). The DMT1 expression observed in inner and outer medulla in healthy mice is similar to that reported by other authors (10, 13). It is important to note that changes in DMT1 expression during development of anemia, more intense under high iron demand, indicate a marked involvement of renal tissue in iron metabolism disease.

Medullar DMT1 localization could be explained by the interdependence known to exist between pH and DMT1 activity (13). Since DCT and collecting ducts are colocalized with a H+-ATPasa (3, 10), their luminal pH can be acidified by the presence of transport coupled to H+. The acid pH in these tubules therefore correlates well with the functional requirements of DMT1.

The most important finding on cortical DMT1 expression in healthy and anemic mice is its localization along the proximal tubule. DMT1 immunostaining, mainly in S2 segments in both healthy and anemic mice, suggests a specific tubular function. In this kidney zone iron transport by DMT1 is also pH dependent, being more active at acid pH; one can therefore expect to find DMT1 in proximal tubules, where the pH of the glomerular filtrate is acid (15).

Coordinated action between Prohepcidin and iron transporters. In view of the relationship between iron metabolism and erythropoiesis described in the literature, the present study sought to further elucidate renal involvement in hemolytic anemia, a condition for which the expression of regulatory peptides in kidney has not as yet been described in depth.

Our initial hypothesis was that in hemolytic anemia, with increased erythropoietic activity, DMT1, MTP1, and Prohepcidin expression is regulated in a coordinated manner (Fig. 4). In this context, we observed a direct relationship between DMT1 and MTP1 in S2 segments under hemolytic crisis, concomitant with reduced Prohepcidin expression in this tubular segment. The regulatory relationship between hepcidin and iron transporters has been widely studied by other authors in several tissues (2, 7, 11). Interestingly, the changes in protein expression observed in renal segments were accompanied by an increase in iron deposits. In this sense, the proximal tubule could be the main renal structure responsible for regulating systemic iron balance in intense erythropoietic demand (Fig. 4).


Figure 4
View larger version (12K):
[in this window]
[in a new window]

 
Fig. 4. Diagram. Renal regulation of iron in anemia. Anemia decreases renal synthesis of Prohepcidin, inducing Ferroportin and DMT1 expression to promote iron reabsorption through proximal cells.

 
The relevance of the proximal tubule in iron balance is supported by a number of studies. Kidney is involved in several metabolic processes that require iron (30). Moreover, the overall capacity for heme biosynthesis, a process requiring iron, presents a decreasing gradient along nephron from cortical to medullar, being primarily associated with the proximal tubule cells (30). This could partly explain the renal expression of iron metabolism proteins in proximal tubules, showing the relevance of these tubular structures in iron homeostasis.

The presence of Prohepcidin in several renal zones both in healthy and anemic mice is an important finding and suggests an intrinsic synthesis of this peptide in kidney, as hypothesized by Kulakzis et al. (16) in healthy mice.

Although the latter authors propose a luminal release of this peptide, the intracellular localization closely associated with basal membrane observed in our study suggests a possible release of the peptide to the bloodstream. Moreover, the behavior of this protein in the anemic state suggests the regulation of hepcidin production, which depends on systemic iron demand.

Since it has been reported in the literature that iron-restricted diets are associated with high renal DMT1 expression and a decrease in urinary iron (34), our evidence of the coincident localization of iron proteins and iron deposits under anemia might indicate the reabsorption of iron from glomerular ultrafiltrate when iron demand is high. The purpose of this mechanism could be the provision of iron to renal cells for their metabolic activity and to help maintain iron homeostasis, emphasizing the importance of renal physiology in hematological processes.

In conclusion, the findings of our study indicate an intrinsic renal synthesis of Prohepcidin in basal conditions which is reduced in anemia and acts in a coordinated manner with MTP1 and DMT1. This behavior, associated with the increment of renal tissular iron, could help to elucidate possible renal involvement in restoration of the hemolytic state.

It will therefore be necessary to carry out further studies to discover the regulatory mechanisms at work between Prohepcidin and iron transporters in the renal tubular system under severe hemolysis.


    GRANTS
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
This study was supported by Secretaría General de Ciencia y Tecnología de la Universidad Nacional del Sur (Grant 24/B116) and by Agencia de Promoción Científica y Tecnológica (FONCYT, Grant-908). T. Veuthey and M. C. D'Anna are Research Fellows of the Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET).


    ACKNOWLEDGMENTS
 
The authors gratefully acknowledge C. Gatti for technical assistance and helpful advice in the immunohistochemistry studies. We thank Dr. B. Galy (European Molecular Biology Laboratory, Germany) for generously providing MTP1 antibody reagents and Dr. S. Gauthier (McGill University, Canada) for providing DMT1 antibody reagents.


    FOOTNOTES
 

Address for reprint requests and other correspondence: M. E. Roque, Laboratory of Human Physiology, Departament of Biology, Biochemistry and Pharmacy, Universidad Nacional del Sur, San Juan 670, 8000 Bahía Blanca, Argentina (e-mail: mroque{at}uns.edu.ar)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


    REFERENCES
 TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Abboud S, Haile D. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem 275: 19906–19912, 2000.[Abstract/Free Full Text]
  2. Anderson GJ, Frazer DM, Wilkins SJ, Becker EM, Millard KN, Murphy TL, McKie AT, Vulpe CD. Relationship between intestinal iron transporter expression, hepatic hepcidin levels and the control of iron absorption. Biochem Soc Trans 30: 724–726, 2002.[CrossRef][Web of Science][Medline]
  3. Brown D, Hirsch S, Gluck S. Localization of a Proton-Pumping ATPase in rat kidney. J Clin Invest 82: 2114–2126, 1988.[Web of Science][Medline]
  4. Canonne-Hergaux F, Gros P. Expression of the iron transporter DMT1 in kidney from normal and anemic mice. Kidney Int 62: 147–156, 2002.[CrossRef][Web of Science][Medline]
  5. Canonne-Hergaux F, Gruenheid S, Ponka P, Gros P. Cellular and subcellular localization of the Nramp2 iron transporter in the intestinal brush border and regulation by dietary iron. Blood 93: 4406–4417, 1999.[Abstract/Free Full Text]
  6. Criswell KA, Sulkanen AP, Hochbaum AF, Bleavins MR. Effects of phenylhydrazine or phlebotomy on peripheral blood, bone marrow and erythropoietin in Wistar rats. J Appl Toxicol 20: 25–34, 2000.[CrossRef][Web of Science][Medline]
  7. Dallalio G, Law E, Means RT. Hepcidin inhibits in vitro erythroid colony formation at reduced erythropoietin concentrations. Blood 107: 2702–2704, 2006.[Abstract/Free Full Text]
  8. Donovan A, Brownlie A, Zhou Y, Shepard J, Pratt SJ, Moynihan J, Paw BH, Drejer A, Barut B, Zapata A, Law TC, Brugnara C, Lux SE, Pinkus GS, Pinkus JL, Kingsley PD, Palis J, Fleming MD, Andrews NC, Zon LI. Positional cloning of zebrafish Ferroportin 1 identifies a conserved vertebrate iron exporter. Nature 403: 778–781, 2000.
  9. Dworkin LD, Brenner BM. The kidney. In: The Renal Circulations, edited by Brenner BM. Philadelphia: Saunders, 1996.
  10. Ferguson CJ, Wareing M, Ward DT, Green R, Smith CP, Riccardi D. Cellular localization of divalent metal transporter 1 in rat kidney. Am J Physiol Renal Physiol 280: F803–F814, 2001.[Abstract/Free Full Text]
  11. Frazer DM, Wilkins SJ, Becker EM, Vulpe CD, McKie AT, Trinder D, Anderson GJ. Hepcidin expression inversely correlates with the expression of duodenal iron transporters and iron absorption in rats. Gastroenterology 123: 835–844, 2002.[CrossRef][Web of Science][Medline]
  12. Ganz T, Nemeth E. Regulation of iron acquisition and iron distribution in mammals. Biochim Biophys Acta 1763: 690–699, 2006.[Medline]
  13. Gunshin H, Mackenzie B, Berger UV, Gunshin Y, Romero MF, Boron WF, Nussberger S, Gollan JL, Hediger MA. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 388: 482–488, 1997.[CrossRef][Web of Science][Medline]
  14. Hara H, Ogawa M. Erythropoietic precursors in mice with phenylhydrazine-induced anemia. Am J Hematol 1: 453–458, 1976.[Web of Science][Medline]
  15. Koeppen BM, Steinmetz PR. Basic mechanisms of urinary acidification. Med Clin North Am 67: 753–770, 1983.[Web of Science][Medline]
  16. Kulaksiz H, Theilig F, Bachmann S, Gehrke SG, Rost D, Janetzko A, Cetin Y, Stremmel W. The iron-regulatory peptide hormone hepcidin: expression and cellular localization in the mammalian kidney. J Endocrinol 184: 361–370, 2005.[Abstract/Free Full Text]
  17. Lacombe C, DaSilva JL, Bruneval P, Fournier JG, Wendling F, Casadevall N, Camilleri JP, Bariety J, Varet B, Tambourin P. Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney. J Clin Invest 81: 620–623, 1988.[Web of Science][Medline]
  18. Latunde-Dada GO, Vulpe CD, Anderson GJ, Simpson RJ, McKie AT. Tissue-specific changes in iron metabolism genes in mice following phenylhidrazine-induced hemolysis. Biochim Biophys Acta 1690: 169–176, 2004.[Medline]
  19. Malyszko J, Mysliwiec M. Hepcidin in anemia and inflammation in chronic kidney disease. Kidney Blood Press Res 30: 15–30, 2007.[CrossRef][Web of Science][Medline]
  20. McKie AT, Barlow DJ. The SLC40 basolateral iron transporter family (IREG1/ferroportin/MTP1). Eur J Physiol 447: 801–806, 2004.[CrossRef][Web of Science][Medline]
  21. McKie AT, Marciani P, Rolfs A, Brennan K, Wehr K, Barrow D, Miret S, Bomford A, Peters TJ, Farzaneh F, Hediger MA, Hentze MW, Simpson RJ. A novel duodenal iron-regulated transporter IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell 5: 299–309, 2000.[CrossRef][Web of Science][Medline]
  22. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, McVey Ward D, Ganz T, Kaplan J. Hepcidin regulates cellular iron efflux by binding to Ferroportin and inducing its internalization. Science 306: 2090–2093, 2004.[Abstract/Free Full Text]
  23. Nicolas G, Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A, Vaulont S. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci USA 98: 8780–8785, 2001.[Abstract/Free Full Text]
  24. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, Beaumont C, Kahn A, Vaulont S. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia and inflammation. J Clin Invest 110: 1037–1044, 2002.[CrossRef][Web of Science][Medline]
  25. Nicolas G, Viatte L, Bennoun M, Beaumont C, Kahn A, Vaulont S. Hepcidin: a new iron regulatory peptide. Blood Cells Mol Dis 29: 327–335, 2002.[CrossRef][Web of Science][Medline]
  26. Oates PS, Jeffrey GP, Basclain KA, Thomas C, Morgan EH. Iron excretion in iron-overloaded rats following the change from an iron-loaded to an iron-deficient diet. Hepatology 15: 665–674, 2000.
  27. Oates PS, Thomas C. Ferroportin is expressed on the mucous granule membrane of a subpopulation of goblet cells in the duodenum of the rat. Histol Histopathol 20: 681–687, 2005.[Web of Science][Medline]
  28. Oates PS, Thomas C. Ferroportin/IREG-1/MTP-1/SLC40A1 modulates the uptake of iron at the apical membrane of enterocytes. Gut 53: 44–49, 2004.[Abstract/Free Full Text]
  29. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, Loréal O. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 276: 7811–7819, 2001.[Abstract/Free Full Text]
  30. Ponka P. Cellular iron metabolism. Kidney Int 55: S2–S11, 1990.[CrossRef]
  31. Roque ME, Sandoval MJ, Aggio MC. Serum erythropoietin and its relation with soluble transferrin receptor in patients with different types of anaemia in a locally defined reference population. Clin Lab Haematol 23: 291–295, 2001.[CrossRef][Web of Science][Medline]
  32. Trinder D, Oates PS, Thomas C, Sadleir J, Morgan EH. Localisation of divalent metal transporter 1 (DMT1) to the microvillus membrane of rat duodenal enterocytes in iron deficiency, but to hepatocytes in iron overload. Gut 46: 270–276, 2000.[Abstract/Free Full Text]
  33. Wareing M, Ferguson CJ, Delannoy M, Cox AG, McMahon RFT, Green R, Riccardi D, Smith CP. Altered dietary iron intake is a strong modulator of renal DMT1 expression. Am J Physiol Renal Physiol 285: F1050–F1059, 2003.[Abstract/Free Full Text]
  34. Wareing M, Ferguson CJ, Green R, Riccardi D, Smith CP. In vivo characterization of renal iron transport in the anaesthetized rat. J Physiol 524: 581–586, 2000.[Abstract/Free Full Text]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
295/4/F1213    most recent
90216.2008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Veuthey, T.
Right arrow Articles by Roque, M. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Veuthey, T.
Right arrow Articles by Roque, M. E.


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.